Aflacin

Quick links to important sections

Aflacin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aflacin

Quick Facts

Property Description
Active Ingredient Ofloxacin (racemic mixture)
Form Tablets, Infusion Solution, Ophthalmic/Otic Solutions
Pharmacological Class Second-generation Fluoroquinolone
Common Purpose Systemic Anti-infective / Antimicrobial Therapy
Origin Synthetic Compound

What Type of Antibiotic is Aflacin?

Aflacin is the commercial designation for the active chemical substance Ofloxacin, which is a synthetic compound known chemically as a quinolone derivative. Ofloxacin is officially classified as a second-generation fluoroquinolone antibiotic, a family of antimicrobial agents noted for their potency and broad spectrum of activity. This classification reflects the compound’s advanced capability compared to earlier generations of quinolones. As a matter of differentiation, Ofloxacin is a racemic mixture containing both the active and inactive forms of the molecule, a characteristic of its pharmacological profile, in contrast to its single active isomer, Levofloxacin.

Composition and Pharmaceutical Forms

The core of the medicine is the active ingredient Ofloxacin, which is a single component product. It is prepared in multiple dosage forms to accommodate various treatment requirements, demonstrating its high utility. These forms include oral film-coated tablets for systemic delivery, sterile solutions for infusion for intravenous administration, and specialized liquid preparations like ophthalmic solutions and otic solutions for targeted topical application. Ofloxacin's established efficacy and safety profile has led to its recognition as a foundational agent in global health, ensuring its availability across diverse formulations.

The General Purpose: Why Ofloxacin is Bactericidal

The general purpose of Aflacin is to provide rapid and definitive antimicrobial therapy by operating as a bactericidal agent; that is, it actively kills susceptible bacteria rather than merely inhibiting their growth. Ofloxacin achieves this by fundamentally disrupting the bacterial cell's core genetic machinery, specifically by inhibiting essential enzymes, such as DNA gyrase and Topoisomerase IV, which are critical for DNA replication and repair. This targeted killing action ensures the source of the infection is eliminated.

Regulatory References

  1. NIH StatPearls on Ofloxacin

What side effects are possible with Aflacin?

Aflacin, containing Ofloxacin, has an officially documented safety profile characterized by adverse reactions grouped by frequency and the physiological systems affected.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their expected rate of occurrence, reflecting data from clinical use and regulatory documents:

  • Uncommon (ge 1/1,000 to <1/100): Include gastrointestinal issues (e.g., nausea, diarrhea, abdominal pain), headache, dizziness, sleep disorder, pruritus, and rash.
  • Rare (ge 1/10,000 to <1/1,000): May involve tendonitis, tendon rupture, anxiety, depression, and other transient nervous system or psychiatric effects.
  • Very Rare or Not Known: This includes severe reactions such as peripheral neuropathy (which can be irreversible), convulsion, severe liver injury, and certain cardiac risks like QT interval prolongation.

Officially Documented Serious Adverse Reactions

The regulatory label highlights several serious adverse reactions, which are critical to the medicine's safety profile. These include tendon rupture (often the Achilles tendon), peripheral sensory neuropathy, Aortic Aneurysm and Dissection, and Exacerbation of Myasthenia Gravis.

Safety Considerations

The official documents define specific contexts that require caution. Older adults and patients concurrently using systemic corticosteroids are documented as having an increased risk of tendon injury. Regulatory texts also advise caution regarding exposure to sunlight or UV light due to the risk of photosensitivity and note potential issues for patients with a history of psychotic disorders or factors predisposing to seizures.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents specify that acute over-ingestion of Aflacin (Ofloxacin) may result in a defined set of documented clinical manifestations. Overdose presentations commonly involve Central Nervous System effects such as drowsiness, dizziness, confusion, and slurred speech, alongside symptoms like nausea and localized reactions such as numbness or swelling of the face.

Severe Outcomes and Monitoring

Acute overexposure poses a risk of severe systemic outcomes, including the documented potential for convulsion (seizure). Furthermore, the official labeling highlights a cardiac risk profile, specifying that an overdose may result in ECG QT prolonged and, potentially, ventricular arrhythmias. Due to this documented cardiac risk, ECG monitoring is required, and continuous hospital monitoring is necessary for observation and management. The risk of increased toxicity is specifically noted for patients with renal impairment due to reduced drug excretion.

Emergency Action

It is documented that no specific antidote is known for Ofloxacin overdose; therefore, management relies on supportive measures. In the event of suspected overexposure, individuals must seek immediate medical attention or immediately consult a physician in an emergency department. Symptomatic and supportive treatment is the primary management strategy. For recent oral overdose, procedural steps may include the consideration of gastric lavage and the administration of activated charcoal to reduce absorption, as described in regulatory documentation.

Therapeutic Uses of Aflacin

What Aflacin Treats: Main Uses and Benefits


The primary therapeutic purpose of Aflacin (Ofloxacin) is its use in situations involving certain distressing symptoms and providing symptomatic support across several organ systems. These applications are relevant within clinical settings that involve acute or disruptive symptom patterns.

Aflacin is commonly used across conditions presenting with acute episodes, which includes support for infections like kidney infection (Pyelonephritis), Urinary Tract Infections (UTIs) associated with acute or disruptive episodes, and Pelvic Inflammatory Disease (PID). It is also relevant for managing skin and soft tissue infections and localized bacterial issues like Otitis Externa (ear) and Conjunctivitis (eye).

This medication is applied in addressing symptom clusters that create noticeable physiological strain, including fever, painful urination, productive coughing, and localized swelling. By offering supportive relief, it helps ease symptoms related to inflammatory or irritative states. The primary benefit is its relevance in contexts marked by increased discomfort or tension, which assists with maintaining functional stability during the acute episode.

“This application supports patients during difficult episodes and contributes to improved comfort during periods of heightened symptoms.”


Quick Fact: Relief for Inflammatory Symptoms

Area of Use Symptom Focus
Urogenital Painful urination, pelvic discomfort, flank pain
Respiratory Productive cough, sputum production, fever
Localized Redness, swelling, purulence, localized tenderness

Regulatory References

  1. NIH LiverTox Overview

Eligibility and Restrictions for Use

Official Eligibility Profile: Aflacin (Ofloxacin)

Regulatory documents define a strict eligibility profile for Aflacin, establishing specific populations for whom use is prohibited and others for whom use is conditional.

Contraindication/Restriction Specific Populations Regulatory Status
Absolute Contraindication History of hypersensitivity to Ofloxacin or any fluoroquinolone; Epilepsy or existing CNS disorders that lower the seizure threshold; Prior history of tendon disorders related to fluoroquinolone use; Children or growing adolescents; Pregnant and breastfeeding women. Prohibited
Age-Related Rule Children/Adolescents (typically under 18) Contraindicated (risk of growth plate cartilage damage)
Conditional Use Patients with Impaired Renal Function (CrCl <50 mL/min) or Severe Hepatic Dysfunction; Geriatric patients; Patients with Myasthenia Gravis Restricted (requires dosage adjustment/close monitoring)

Eligibility to use Aflacin is generally limited to the adult population (18+ years) who do not possess any of the specified absolute contraindications. Use in patients with kidney or liver impairment is not prohibited but is restricted to require regulatory-mandated dose adjustments.

What should I know about interactions with other medicines?

The official regulatory profile for Aflacin (Ofloxacin) describes interactions structured around modifications to its bodily presence (pharmacokinetics) and the augmentation of specific risks (pharmacodynamics).

Absorption and Timing Rules

Co-administration with products containing metal cations results in chelation, a process that substantially interferes with Ofloxacin absorption, reducing systemic exposure. This includes Antacids (containing aluminum or magnesium), Sucralfate, and supplements containing Iron or Zinc. A mandatory timing requirement is established: these products must not be taken within the two-hour period before or the two-hour period after Aflacin administration. General food intake does not affect total exposure but prolongs the time to peak concentration.

Pharmacodynamic and Clearance Interactions

Several drug combinations require caution due to pharmacodynamic augmentation. Use with Corticosteroids increases the documented risk of tendon rupture. Concomitant use with drugs that prolong the QTc interval (e.g., certain antiarrhythmics) may cause an additive effect on the QTc interval. Co-administration with Theophylline or certain NSAIDs (e.g., Fenbufen) may contribute to a lowering of the cerebral seizure threshold. Pharmacokinetic interaction with Probenecid reduces Ofloxacin's clearance, increasing its systemic exposure. Monitoring of blood tests is required for co-administration with Vitamin K Antagonists (e.g., Warfarin) and Sulfonylureas (e.g., Glibenclamide) due to risks of increased bleeding or hypoglycemia, respectively.

Mechanism of Action

Molecular Target Engagement: Inhibiting Bacterial DNA Synthesis

Aflacin acts within domains involving enzyme-mediated signaling by specifically targeting the bacterial enzymes DNA gyrase (Topoisomerase II) and Topoisomerase IV . DNA gyrase manages the topological state of bacterial DNA, which is essential for replication and transcription.


Mechanistic Cascade: Arresting Bacterial Cell Division

The drug initiates a signaling sequence suppression by binding to the DNA-enzyme complex, stabilizing it in a non-functional state. This action modifies early molecular steps, thereby disrupting the essential DNA replication, transcription, and repair processes within the bacterial cell. This mechanism restricts overactive, dysregulated bacterial proliferation by establishing a non-functional enzyme-DNA complex.


Pathway Effects: Disrupting DNA Strand Integrity

Disruption of DNA gyrase and Topoisomerase IV activity interferes with the necessary separation of daughter chromosomes during the final stages of cell division. This cascade promotes the accumulation of DNA strand breaks, resulting in a loss of cellular viability. These molecular events define the resulting pathway modulation.

Dosage and Administration Information

Aflacin (Ofloxacin) is administered through distinct routes, depending on the target site. For systemic therapy, the medicine is provided in film-coated oral tablets (in strengths such as 200 mg to 400 mg). Specialized 0.3% topical solutions are used for localized administration in the eye (ophthalmic) or ear (otic).

Standard Dosing Principles

The general principle for systemic use involves administration twice daily (every 12 hours) to maintain consistent drug levels. A single daily dose may be used only when the total dose is 400 mg or less. The maximum daily dose is 800 mg. The total duration of use is determined by the specific condition, ranging from short courses of 3 days up to 6 weeks for chronic infections, and therapy should not exceed 2 months overall.

Administration Context

Oral tablets may be taken with or without food. However, official instructions mandate that administration must be separated by at least 2 hours from consuming products containing metal cations, such as antacids or supplements containing magnesium, iron, or zinc, to avoid reduced absorption. For ophthalmic application, if other topical eye medications are used, an interval of 10 to 15 minutes is required between instillations.

Population Adjustments

Official instructions mandate specific dose adjustments for patients with impaired kidney (renal) function. For systemic use, this often involves a reduction in the daily dose or an extension of the dosing interval to every 24 hours. Dosing regimens for older adults are also subject to modification based on a review of their renal status.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aflacin

The research for Aflacin (Ofloxacin) has primarily used Randomized Controlled Trials (RCTs) to observe how clinical signs and measured outcomes evolved over defined time periods in group settings. These studies help show what has been observed so far.


Evidence for Systemic Use in Urinary Tract and Kidney Infections

Research has explored Ofloxacin for Urinary Tract Infections (UTIs) and Kidney Infections (Acute Pyelonephritis). RCTs evaluated the elimination of bacteria (microbiological eradication) and the observed patterns of change in severe symptoms. What remains uncertain is the necessity for ongoing evaluation of effectiveness due to the growing emergence of antimicrobial resistance globally. Follow-up assessments typically concluded within 30 days post-treatment.


Evidence for Treatment of Pelvic Inflammatory Disease (PID)

Studies monitored clinical response and microbiological clearance in women with mild-to-moderate PID. Research explored the measurement of clinical outcomes for Ofloxacin-containing regimens alongside other treatment options. What remains uncertain is that follow-up durations were limited, resulting in limited information for long-term outcomes related to reproductive health.


Evidence for Localized Use (Ear and Eye)

The topical forms (ear and eye solutions) were evaluated in separate, controlled trials. Studies monitored outcomes related to physical discomfort and the elimination of common bacteria in localized infections.

Research Data in Pediatric and Topical Populations

Evidence included pediatric patients (as young as 6 months) in otitis externa research, exploring the use of the solution in these age groups and monitoring the drug's limited distribution beyond the local area of application.


Areas of Research Uncertainty and Study Limitations

Research limitations include: Outcomes Consistency, where the definition of "clinical cure" has varied across studies. Bacterial Resistance requires continuous re-evaluation. Data for certain groups, such as patients with complex comorbidities, remain insufficient, and long-term effects are not fully established.

Key Studies & References

  1. Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines (UTI Evidence Review)
  2. 2017 European guideline for the management of pelvic inflammatory disease (PID Guidance)

Frequently Asked Questions (FAQ)

Common questions about Aflacin (FAQ)

Q: How is Aflacin different from similar medications for the same purpose?

Official information describes Aflacin (Ofloxacin) as a racemic mixture (containing both the active and an inactive form of the molecule). A similar drug, Levofloxacin, is the single, isolated active form (isomer). Research suggests that Levofloxacin may have better activity against certain respiratory pathogens.


Q: What is the expected timeline for Aflacin to start working?

According to the official prescribing information, after taking the oral tablet, the drug reaches its highest concentration in the bloodstream approximately one to two hours after administration. Observed changes in clinical signs are influenced by the specific condition being addressed.


Q: How long does the effect of one dose of Aflacin typically last?

The official recommended schedule is based on the drug's half-life, which is approximately 9 hours. The recommended dosing frequency (often twice daily) is designed to maintain consistent and appropriate drug levels in the body over the course of the treatment.


Q: Are there any major diet restrictions or food types to avoid when taking Aflacin?

Official instructions state that Aflacin oral tablets may be taken either with or without food. There are no general food types listed as being restricted while taking this medication. Alcohol is not listed as a specific interaction or restriction in the official safety warnings.


Q: Is it normal to feel a mild headache when first starting Aflacin?

Headache is listed as an uncommon adverse reaction (reported in less than 1 in 100 patients) in official documents. While this is a documented possibility, the safety profile does not specify if this particular reaction occurs more frequently at the start of therapy.


Q: Is Aflacin safe for children, based on official labeling?

No. The official documents clearly state that Aflacin is contraindicated (prohibited) for use in children and growing adolescents. This prohibition is based on a documented safety concern regarding the potential for damage to the cartilage in weight-bearing joints in this age group.


Q: Can Aflacin be crushed or chewed if a person has difficulty swallowing pills?

Aflacin is provided as film-coated oral tablets. Crushing film-coated tablets can change how the medicine is absorbed by the body and may cause localized irritation. Therefore, official guidelines generally recommend taking the tablets whole as intended.


Q: Does Aflacin interact with birth control pills?

Official product information for Aflacin does not usually list specific interactions with oral contraceptives. However, a theoretical concern exists that broad-spectrum antibiotics, including this class of drug, may reduce the effectiveness of estrogen-containing birth control pills. Given this, consulting official product information for clarity regarding concurrent use is generally recommended.


Q: Is it required to take Aflacin at the exact same time every day?

The recommended regimen is often twice daily (such as every 12 hours) to ensure consistent drug levels are maintained in the body. Official information emphasizes separating the administration intervals but does not typically mandate taking the dose at the exact same time each day.


Q: Is Aflacin available as a generic version?

Yes. Aflacin (Ofloxacin) is available in generic form. The original brand-name version of the oral tablet was discontinued by the manufacturer in the United States, but the generic version remains widely available.


Q: What is the legal classification of Aflacin (e.g., prescription-only or over-the-counter)?

Aflacin is designated as a prescription-only drug in major health jurisdictions worldwide. It is officially classified as an 'Rx-only' drug and cannot be legally purchased without an authorized prescription.


Q: Are there any specific laboratory tests recommended while taking Aflacin?

For most individuals, routine lab tests may not be required. However, official documents advise that individuals taking certain interacting medications, such as blood thinners (Vitamin K Antagonists) or certain diabetes medications (Sulfonylureas), should have their blood tests monitored closely.


Q: Is Aflacin considered a first-line treatment for its indication?

For certain common conditions, such as uncomplicated urinary tract infections (UTIs), regulatory documents advise that fluoroquinolones like Ofloxacin should be reserved for patients who have limited or no alternative treatment options. This is done to mitigate risks and slow the development of resistance.


Q: What should be done if an allergic reaction to Aflacin is suspected?

Official safety warnings instruct that if any signs of a severe hypersensitivity or allergic reaction occur, the drug must be immediately discontinued. If a severe hypersensitivity or allergic reaction is suspected, official instructions mandate the immediate discontinuation of the drug and seeking emergency medical attention.


Q: Are there different strengths or formulations of Aflacin available?

Yes, Aflacin (Ofloxacin) is available in various forms to suit different needs. This includes several strengths of oral tablets (e.g., 200 mg, 300 mg, and 400 mg), and specialized topical solutions for use in the eye or ear.


Q: Is it possible for Aflacin to stop working after a period of time?

Official documents contain warnings that using any antimicrobial drug can contribute to the development of drug-resistant bacteria. Regulatory information emphasizes that the drug is intended for use when an infection is strongly suspected to be caused by susceptible bacteria.


Q: Is Aflacin a relatively new medication or has it been on the market for a long time?

Aflacin (Ofloxacin) is a well-established medication that has been on the market for a significant duration. The original compound received approval from the U.S. Food and Drug Administration (FDA) in December 1990.


Q: Is there any public information regarding lawsuits or major safety reviews for Aflacin?

Major regulatory bodies, such as the FDA, have released Safety Communications regarding the class of drugs to which Aflacin belongs (fluoroquinolones). These communications have led to updates in the official drug labels, describing the risk of disabling and potentially serious side effects.


Q: What is the average duration of treatment with Aflacin for its primary indication?

The total duration of treatment is highly dependent on the condition. For common uses, such as certain uncomplicated urinary tract infections, official labeling often describes a short course of therapy, sometimes as brief as three days, though treatment can extend for several weeks for more complex infections.

How should Aflacin be stored and disposed of?

How to Store and Dispose of Aflacin?

The official storage conditions for Aflacin (Ofloxacin) are determined by regulatory documentation to ensure product integrity and safety.


️ Storage Requirements

Storage Component Requirement
Temperature Store at controlled room temperature (20 C to 25 C / 68 F to 77 F).
Prohibition Do not freeze any solution forms; this is explicitly stated to prevent product degradation.
Protection Keep in the original container, protected from excessive moisture and light.
Child Safety The product must be stored out of the sight and reach of children.

️ Disposal Instructions

Unused or expired Aflacin must be disposed of according to labeled regulatory guidance. Patients should utilize an official drug take-back program or authorized collection site. Disposal must follow rules to prevent environmental contamination; the medicine must not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aflacin found in:

A-Z Index: